Here's some of what is coming soon to NeurologyLive® this week.
Feature|Videos|October 12, 2026
Publishing Starts in the Clinic
How clinicians can turn everyday observations into publishable research: spotting the gap, choosing the right paper type, and drafting a first manuscript.
Advertisement
Advertisement
Many clinicians assume that publishing requires a large, sophisticated trial. It does not. Most research begins with the kind of observation that happens in an ordinary clinic week: an unusual symptom or cluster of symptoms, an unexpected response to a therapy, a new program for managing symptoms, or a treatment studied in another disease and applied to the people you see every day.
Related to this article
Test your neurology knowledge with NeurologyLive®'s weekly quiz series, featuring questions on a variety of clinical and historical neurology topics. This week's topic is recent therapeutic advances in MS!
Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending October 9, 2026.
Carmela Tartaglia, MD, FRCPC, discusses the challenges of diagnosing frontotemporal dementia, the evolving role of biomarkers, and emerging approaches to disease modification.
Catch up on any of the neurology headlines you may have missed in September 2026, compiled into 1 place by the NeurologyLive® team.
Newly announced Phase 4 THRIVE trial results showed most patients who previously had an inadequate response to a CGRP-targeting therapy improved with eptinezumab over 24 weeks.
Phase 3 ARISE trial results show solengepras 150 mg significantly reduced OFF time and improved motor and non-motor symptoms in Parkinson disease.
New cerebrospinal fluid biomarker data suggest shared LRRK2 pathway activation across sporadic and LRRK2-associated Parkinson disease, potentially informing biomarker development and therapeutic targeting.
Advertisement
Advertisement